The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZYME | +35.91% | -54.94% | -14.74% | +41% |
| S&P | +14.84% | +96.04% | +14.41% | +182% |
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab’s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
The biotech stock's shares may have been pushed by a short squeeze.
Investors applauded a major licensing deal with Jazz Pharmaceuticals.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $48.73M | 153.2% |
| Gross Profit | $45.51M | 172.3% |
| Gross Margin | 93.40% | 6.5% |
| Market Cap | $881.68M | 45.4% |
| Market Cap / Employee | $3.23M | 47.5% |
| Employees | 273 | 0.0% |
| Net Income | $2.32M | 106.1% |
| EBITDA | $2.54M | 111.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.25M | 38.5% |
| Accounts Receivable | $2.63M | -91.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.09M | -12.4% |
| Short Term Debt | $3.59M | 26.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.95% | 4.2% |
| Return On Invested Capital | -30.80% | 4.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.71M | 146.6% |
| Operating Free Cash Flow | $12.23M | 149.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.21 | 2.80 | 2.44 | 2.71 | 95.72% |
| Price to Sales | 15.36 | 14.32 | 9.59 | 7.90 | -23.77% |
| Price to Tangible Book Value | 2.32 | 2.95 | 2.57 | 2.84 | 88.05% |
| Enterprise Value to EBITDA | -21.51 | -47.81 | -29.10 | 278.90 | -1992.29% |
| Return on Equity | -28.7% | -30.5% | -29.8% | -19.9% | -24.40% |
| Total Debt | $20.25M | $18.51M | $18.46M | $18.68M | -6.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
